IDEAS home Printed from
   My bibliography  Save this article

A cost-benefit analysis of relocating a polluting factory


  • Doron Lavee


This study examines the economic viability of relocating polluting industrial factories from densely populated residential areas to designated industrial zones. This solution requires a significant economic investment consisting of relocating and remediating costs. This solution has a direct financial benefit, due to the alternative value of the land on which the factory currently stands, as it can be converted to more attractive uses. In many cases, this direct benefit does not cover the costs, therefore it is not economically feasible to transfer the plant. However, it is possible that relocating a factory in these cases is economically feasible from a national perspective, as the factory's current location may cause a decline in nearby property values, while relocating it may result in an increase in property values. Nevertheless, in these cases, government intervention may be required. This paper presents a case study for such a situation -- analysing the case of the Ta'as Magen factory, a severely polluted site located in the heart of Israel's main metropolitan area. This analysis reveals that the indirect benefits of relocating the factory and remediating the site are considerably greater than the direct benefits, and outweigh all required costs.

Suggested Citation

  • Doron Lavee, 2012. "A cost-benefit analysis of relocating a polluting factory," Journal of Environmental Planning and Management, Taylor & Francis Journals, vol. 55(7), pages 901-919, October.
  • Handle: RePEc:taf:jenpmg:v:55:y:2012:i:7:p:901-919 DOI: 10.1080/09640568.2011.632677

    Download full text from publisher

    File URL:
    Download Restriction: Access to full text is restricted to subscribers.

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    1. Frances Ruane & Xiaoheng Zhang, 2007. "Location Choices of the Pharmaceutical Industry in Europe after 1992," The Institute for International Integration Studies Discussion Paper Series iiisdp220, IIIS.
    Full references (including those not matched with items on IDEAS)

    More about this item


    Access and download statistics


    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:taf:jenpmg:v:55:y:2012:i:7:p:901-919. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Chris Longhurst). General contact details of provider: .

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.